Citations

Clear

4847 citation(s) found for "Tu, Eric".

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action
Graff‐Radford, Jonathan, Boon, Baayla D. C., Westman, Eric, Groot, Colin, Jones, David T., Grinberg, Lea T., Rabinovici, Gil D., Whitwell, J R, Apostolova, L G, Mj, Murray, Hammers, Dustin B., Schindler, Suzanne E., Atonsdottir, Inga, Schott, J J, Illán‐Gala, Ignacio, Chukwuanugo, Ogbuagu, Guerra, Jorge J. Llibre, Peters, Ruth, Abner, Erin L., Abdelnour, Carla , A, Cortes Llado, Joie, Renaud La, Souza, Leonardo Cruz de, Shir, Dror , Pijenburg, Yolande A. L., Carrillo, Maria C., Dickerson, Bradford C, Aisen, P, Ossenkoppele, Rik, Raman, Rema, Joie, Renaud La , Corriveau-Lecavalier, Nick , La Joie, Renaud , Shir, Dror , Corriveau‐Lecavalier, Nick , Falgàs, Neus , Putcha, Deepti , Graff‐Radford, Jonathan , Yong, Keir , Boon, Baayla D.C. , Mohanty, Rosaleena , Westman, Eric , Groot, Colin , Jones, David T. , Grinberg, Lea T. , Rabinovici, Gil D. , Whitwell, Jennifer L. , Apostolova, Liana G. , Hammers, Dustin B , Schindler, Suzanne E. , Rhodus, Elizabeth K. , Illán‐Gala, Ignacio , OGBUAGU, CHUKWUANUGO, Abner, Erin L. , Souza, Leonardo Cruz de , Rezaii, Neguine , Carrillo, María C. , Dickerson, Bradford Clark , Aisen, Paul , Ossenkoppele, Rik , Raman, Rema

Mayo Clinic

Alzheimer's & Dementia | June 23, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71521 | PMID 42334062 Get It

Abstract Patients with atypical variants of Alzheimer's disease (AD) often present at a younger age with predominantly non‐amnestic impairments and a more aggressive disease course. Historically, individuals with atypical presentations have not been included in large‐scale clinical trials, which typically focus on late‐onset, sporadic amnestic‐predominant AD. Consequently, treatment options and research efforts specific to atypical AD remain limited. The emergence of amyloid‐targeting therapies that slow disease progression underscores these challenges, as evidence supporting their efficacy in early‐onset amnestic and non‐amnestic AD variants is scarce. This perspective article argues that atypical AD represents an excellent disease model for clinical trials and proposes strategies to address critical gaps in clinical trial design for this population. Key considerations include optimizing participant selection approaches, establishing syndrome‐specific or surrogate biological and clinical endpoints, and fostering advocacy to enhance early and accurate diagnosis, equitable representation, and outcomes for these populations.
Post-ERCP pancreatitis after self-expanding metal stent placement in patients with pancreatic versus non-pancreatic malignant biliary obstruction
AbiMansour, Jad P. , Petersen, Bret T. , Valls, Eric J. Vargas, Law, Ryan, Han, Samuel, AbiMansour, Jad , Vargas Valls, Eric J, Petersen, Bret T. , Vargas, Eric J. , Law, Ryan, Chandrasekhara, Vinay

Mayo Clinic

Therapeutic Advances in Gastrointestinal Endoscopy | June 23, 2026 | Volume: 19 | Issue: No issue available | Pages: No page available

10.1177/26317745261458987 | PMID 42368878 Get It

Background: Self-expanding metal stents (SEMS) are recommended for the endoscopic palliation of distal malignant biliary obstruction (DMBO). Placement of SEMS during endoscopic retrograde cholangiopancreatography (ERCP) has been associated with an increased risk of post-ERCP pancreatitis (PEP). Objectives: The aim of this study is to evaluate rates of PEP in patients who underwent SEMS placement for pancreatic versus non-pancreatic malignancy. Design: Retrospective Cohort Study. Methods: Patients who underwent SEMS placement for DMBO between June 2017 and May 2021 were identified retrospectively from a procedural billing database. PEP incidence was compared between pancreatic and non-pancreatic DMBO groups and multivariate logistic regression was performed to identify risk factors for PEP. Results: A total of 488 individuals were identified, with 395 (80.9%) cases of DMBO due to pancreatic and 93 (19.1%) due to non-pancreatic malignancy. Stent types included 124 (25.4%) fully covered (FCSEMS) and 364 (74.6%) uncovered metal stents (UCSEMS). The overall rate of PEP in the cohort was 6.3% with no significant difference between pancreatic and non-pancreatic etiologies (6.1% vs 7.5%, p = 0.606). When adjusted for age <50 years old, female sex, and pancreatic stent placement, a non-pancreatic malignancy was not associated with an increased risk of PEP (OR 0.83, 95% CI 0.36–2.15). Conclusion: No statistically significant difference in PEP rates was seen after biliary sphincterotomy and SEMS placement for palliation of DMBO in patients with pancreatic versus non-pancreatic malignancies.
Assessment of psychological and physiological responses to auditory and visual stimuli during recovery from acute stress induction
Snyder, Eric M. , Son, Young Joo , Byun, Kunjoon , Snyder, Eric M , Li, Linhao, West, Colin P. , Mazurek, Kevin A.

Mayo Clinic

Physiology International | June 23, 2026 | Volume: 113 | Issue: 2 | Pages: 277-298

10.1556/2060.2026.00801 | PMID 42334880 Get It

Abstract Workplace stress is one of the main sources of stress for adults, although physiological and cognitive factors may impact each person's stress response. Numerous studies have shown heart rate, heart rate variability, neural activity, and cognitive performance are affected by stress. Additionally, visual and auditory stimuli in one's environment have been shown to affect individuals' reaction to stressful events. To our knowledge, few studies have examined how each of these physiological and cognitive measures relate to one's perception of stress, the ability to recover from stress, and what environmental factors may help with stress recovery. Here, 80 healthy adults performed a laboratory-controlled stress induction task where they experienced and recovered from an acute psychological stressor (Trier Social Stress Test, TSST, using verbal math skills and a public presentation that was videotaped). Throughout the assessment, heart rate, heart rate variability, and neural activity were measured using wearable devices to assess changes before, during, and after the stressor. Additionally, participants were assessed their perceived stress levels at specific times throughout the assessment. After the psychological stressor, participants were randomly assigned to one of four recovery conditions within a multisensory relaxation room: Control (C), Auditory Only (A), Visual Only (V), or Combined Auditory and Visual (AV). During the stressor, anxiety, heart rate, and beta EEG power increased and high-frequency power and heart rate variability decreased, confirming participants reactivity to the stressor ( P < 0.01 for all vs. baseline). Only the V and AV conditions led to notable reductions in anxiety (15 and 17%, respectively) vs. the C condition, but these did not reach statistical significance. There was no difference between V and AV, suggesting a stronger impact of V. We observed no differences between conditions during recovery for HR and HRV. Overall, these findings suggest the visual features of the relaxation room impacted self-reported anxiety, however physiological and neurological effects did not demonstrate a statistically meaningful response.
Real‐world, multi‐omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)
Sauta, Elisabetta, Lanino, Luca, Bewersdorf, Jan P, Kewan, Tariq, Ali, Najla H. Al, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Brunner, Andrew M., Kuykendall, Andrew T., Bennett, John M. , Buckstein, Rena, Bejar, Rafael, Carraway, Hetty E., DeZern, Amy E., Hasserjian, R., Loghavi, Sanam, Odenike, Olatoyosi, Padron, Eric , Patnaik, Mrinal M., Stahl, Maximilian, Sekeres, M., Steensma, David P., Savona, Michael R., Taylor, Justin, Xu, Mina L., Sallman, David A., Nimer, Stephen D. , Hourigan, Christopher S., Wei, Andrew H., Riva, Elena , Ventura, Denise, Pinocchio, Nicole, Buizza, Alessandro , Russo, Antonio, D'Amico, Saverio, Delleani, Mattia , Travaglino, Erica , Tentori, Cristina A., Ferrari, Ivan, Crespi, Alessandra, Figini, Giulia , Matteo, Maria Di, Milanesi, Chiara, Castellani, Gastone, Borate, Uma M., Gore, Steven D., Kim, Tae K., Loosdrecht, Arjan A. van de , Daver, N., Wang, Sa A. , Foucar, Kathryn, Iastrebner, Marcelo, Miyazaki, Yasushi, Al‐Kali, Aref, Mittelmann, Moshe, Cluzeau, Thomas , Ades, Lionel, Germing, Ulrich, Garcia‐Manero, Guillermo, Kordasti, Shahram, Haferlach, Torsten, Zeidan, Amer M., consortia, An international study on behalf of GenoMed4all, Synthema, and icMDS, Zeidan, Amer M. , Buizza, Alessandro , Ficara, Francesca , Efficace, Fabio , Diez-Campelo, Maria , Orfao, Alberto , Wang, Sa A , Cluzeau, Thomas , Komrokji, Rami S , Della Porta, Matteo Giovanni , Zeidan, Amer M , Maggioni, Giulia , Todisco, Gabriele , Sauta, Elisabetta , Lanino, Luca , Ball, Somedeb , Bewersdorf, Jan Philipp , Fenaux, Pierre , Platzbecker, Uwe , Santini, Valeria , Xie, Zhuoer , Brunner, Andrew M. , Kuykendall, Andrew , Buckstein, Rena , Bejar, Rafael , Carraway, Hetty E. , Dezern, Amy Elizabeth , Griffiths, Elizabeth A. , Halene, Stephanie , Hasserjian, Robert P. , List, Alan F. , Loghavi, Sanam , Odenike, Olatoyosi , Patnaik, Mrinal M. , Roboz, Gail J. , Sekeres, Mikkael A. , Steensma, David P. , Savona, Michael R. , Sallman, David A. , Hourigan, Christopher S. , Wei, Andrew H. , Campagna, Alessia , Ubezio, Marta , Ventura, Denise , Pinocchio, Nicole , Zampini, Matteo , Russo, Antonio , Pesce, Francesco , D'Amico, Saverio , Asti, Gianluca , Tentori, Cristina Astrid , Ferrari, Ivan , Matteo, Maria Di, Brindisi, Matteo , Manes, Nicla , Crisafulli, Laura , Ficara, Francesca , Castellani, Gastone , Borate, Uma , Efficace, Fabio , Gore, Steven D. , Díez‐Campelo, María , Rozman, Marı́a , Órfão, Alberto , Foucar, Kathryn , Iastrebner, Marcelo , Scheinberg, Phillip , Miyazaki, Yasushi , Madanat, Yazan F. , Al‐Kali, Aref , Mittelman, Moshe , Adès, Lionel , Germing, Ulrich , Garcia‐Manero, Guillermo , Kordasti, Shahram , Haferlach, Torsten , Komrokji, Rami S.

Mayo Clinic

HemaSphere | June 22, 2026 | Volume: 10 | Issue: 6 | Pages: No page available

10.1002/hem3.70406 | PMID 42339339 Get It

Abstract Myelodysplastic syndromes (MDS) are clinically and biologically diverse disorders, emphasizing the need for personalized treatment approaches. The International Working Group for Prognostication of MDS (IWG_PM) recently introduced a molecular classification, referred to as the MDS taxonomy, that categorizes patients into 16 subgroups based on 21 gene mutations, 6 cytogenetic abnormalities, and loss of heterozygosity (LOH) at TP53 and TET2 loci. This study sought to validate and enhance the clinical relevance of the MDS taxonomy by analyzing a large retrospective cohort ( n = 5136) and transcriptomic data from a prospective cohort ( n = 477). The taxonomy successfully identified subgroups with distinct clinical characteristics and disease progression patterns. However, incorporating gene interactions from taxonomy subgroups did not improve the prognostic performance of the Molecular International Prognostic Scoring System (IPSS‐M). We further assessed whether the taxonomy could guide management in patients receiving disease‐modifying therapies. Except for the “ TP53 ‐complex” subgroup, taxonomy classifications were not predictive of hypomethylating agent response or transplant outcomes. Nonetheless, they correlated with overall survival, suggesting that while both IPSS‐M and the taxonomy capture disease biology, other non‐genetic factors may influence treatment response. RNA sequencing confirmed the biological distinctiveness of the taxonomy groups. Transcriptomic profiling of CD34+ bone marrow cells revealed unique, homogeneous gene expression patterns, particularly within the AML‐like, bi TET2 , SF3B1 , and TP53 ‐complex subgroups. Further integration of multi‐omics data may refine MDS classification, improving clinical decision‐making and guiding the development of targeted therapies.
Immune Checkpoint Inhibitor–Associated Myocarditis: A Retrospective Case Series
Monsanto, Michael Acevedo , Schneider, Artur, Chirilă, Răzvan M. , Ganguly, Paulamy , Lopez, Camily Morales, Zuberi, Eric C., Schneider, Artur , Zuberi, Eric

Mayo Clinic

Romanian Journal of Internal Medicine | June 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2478/rjim-2026-0013 | PMID 42324828 Get It

Abstract Background Immune checkpoint inhibitors (ICIs) improve outcomes across malignancies but can cause immune-related adverse events (irAEs), notably myocarditis, with case-fatality up to 50% Methods We retrospectively reviewed five patients with potential ICI-associated myocarditis treated at Mayo Clinic Florida (2019–2024) and summarize the existing literature. Cases were retrospectively categorized as definite, probable, or possible myocarditis according to cardiac magnetic resonance (CMR) findings and histopathology when available. Results The median age was 74 years, and four of the five patients were male. Myocarditis developed between 5 and 30 days after initiation of anti–PD-1 therapy. Presentations included dyspnea (three patients), chest pain (one patient), and asymptomatic troponin elevation detected on routine monitoring (one patient). Troponin T elevation above the 99th percentile was seen in all five cases (normal <= 15 ng/L). Electrocardiograms (ECG) demonstrated conduction abnormalities or ventricular ectopy in each patient. Left ventricular ejection fraction was preserved in four patients and severely reduced in one. CMR provided findings supportive of myocarditis in two of the five cases, while one endomyocardial biopsy (EMB) was performed and did not demonstrate active inflammation. Based on predefined criteria, one case was classified as definite myocarditis, one as probable, and three as possible ICI-associated myocarditis. All five patients received corticosteroid therapy. Two required escalation of immunosuppression. One patient developed concurrent myasthenia gravis, consistent with myocarditis–myositis–myasthenia (MMM) overlap, and underwent plasmapheresis for the neuromuscular component. Three patients recovered. Two patients died during follow-up; in both cases, myocarditis was considered a contributing factor, although direct causality could not be definitively established.
Pulmonary Flow Distribution in Patients Following Hemi‐Mustard and Bidirectional Glenn Using Quantitative 4D Flow Particle Tracking
Schuppen, Joost van , Kuipers, Irene M. , Hulst, Annelies E. van der , Blom, Nico A. , Palen, Roel L.F. van der , Groenink, M, Planken, R. Nils , Ooij, Pim van , Schrauben, Eric , van Schuppen, Joost , Kuipers, I M , Hazekamp, M G , van der Hulst, A E , Blom, Nico A , van der Palen, R L F , Planken, R Nils , van Ooij, P , Schrauben, Eric M , Groenink, Maarten

Mayo Clinic

Journal of Magnetic Resonance Imaging | June 20, 2026 | Volume: 64 | Issue: 3 | Pages: 867-870

10.1002/jmri.70386 | PMID 42322666 Get It

Elective genomic sequencing for adults in research, clinical and commercial contexts
Linderman, Michael D. , Adelson, Sophia , Berro, Tala , Crawford, Scott , Cunningham, Tshaka J., Esplin, Edward D. , Ewing-Crawford, Altovise T, Nielsen, Daiva E. , Andrighetti, Heather, Bleyl, Steven B., Haverfield, Eden , Hegde, Madhuri , Konstantinos, Lazaridis N, Leonard, Debra G. B. , May, Thomas , McGinniss, Molly, Pandya, Vaibhav, Schadt, Eric E. , Zettler, Bethany , Team, PeopleSeq Study, Adelson, Sophia M , Berro, Tala M , Crawford, Scott D , Esplin, Edward D , Nielsen, Daiva E , Pereira, Stacey , Schmidlen, Tara , Haverfield, Eden V , Hegde, Madhuri , Kruszka, Paul , Leonard, Debra , May, Thomas , Schadt, Eric E , Tzovaras, Bastian Greshake , Zettler, Bethany , McGuire, Amy L , Green, Robert C. , Berro, Tala M., Anderson, Jennifer L., Cunningham, Tshaka, Ewing, Altovise T. , Nielsen, Daiva E., Church, George M. , Konstantinos, Lazaridis N., McGinniss, Molly A. , Schadt, Eric E., Green, Robert C., Juusola, Jane , McWalter, Kirsty , Esplin, Ed, Haverfield, Eden, Hazell, Allison, Gu, Jessica, Hogan, Jennifer, Church, George , Ball, Mad Price , McGinnis, Molly, Schadt, Eric, Linderman, Michael, McGuire, Amy, Christensen, Kurt D. , Caskey, Thomas, Zoltick, Emilie S. , Crawford, Scott, Young, Robert, Hunsanger, Jillian, Bradley, Sophia, Cunningham, Tshaka, Roberts, Scott, Ricks‐Santi, Luisel , Lillard, James, Washington, Kareem N., Johnson, Anthony

Mayo Clinic

No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.09.26355296 | PMID 42369514 Get It

Abstract Purpose Elective genomic sequencing (EGS) returns monogenic disease findings in multiple genes, including potentially novel variants, and may also provide participants with carrier status, pharmacogenomic and other health-related information. The PeopleSeq Study assessed participants’ motivations for and concerns about EGS and the associated clinical and psychosocial outcomes across diverse EGS providers. Methods We administered a shared questionnaire to participants who chose to undergo EGS via 18 academic, clinical, or commercial EGS platforms. Results We enrolled 1575 participants, of whom 1147 (72.8%) completed a questionnaire after receiving their EGS results. A majority (60.3%) of the participants who completed a post-result questionnaire self-reported receiving results they assessed as important, including negative findings, and 75.9% reported a form of health-related utility. Among a subset (19.4%) who shared their EGS reports, 16.6% (37 of n =223) received a monogenic finding and self-reported results deemed “important” were consistent with EGS reports. Most participants (74.1%) discussed their results with their family, but fewer discussed their results with a healthcare provider other than the site team (41.7%) or had one or more medical visits as a direct result of their EGS testing (23.1%). Participants expressed diverse motivations for EGS, with 91.4% expressing interest in their personal disease risk and 54% who expressed quasi-indication-based motivations related to family medical history. Individuals motivated by family history reported important results at a significantly higher rate. Conclusions Early adopters of EGS are motivated by general interest in their health as well as quasi-indication-based considerations such as family history. A majority of participants learned results they considered medically important, but a much smaller segment engaged healthcare providers with their results.
Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma
Wang, Chang , 吴得红, Tzankov, Alexandar, Møller, Michael , Visco, Carlo , Hsi, Eric D. , Zhao, Xiaoxian , Lv, Beibei, Wang, Bangchen , Yao, Shuna, Chiu, April , Dybkær, Karen , Bhagat, Govind , Montes-Moreno, Santiago, Pan, Zenggang , Bernal‐Mizrachi, Leon , Krieken, J Han JM van, Choi, William W.L., Tam, Wayne , Chen, Weina , Ponzoni, Maurilio, Ferreri, Andrés J.M. , Khajouei, Farzaneh , Sikkink, Kristin , Schmitt, Anthony D. , Xu-Monette, Zijun Y , Møller, Michael Boe , Visco, Carlo , Hsi, Eric D , Lv, Beibei , Wang, Bangchen , Chiu, April , Dybkaer, Karen , Bhagat, Govind , Chen, Weina , Parsons, Benjamin M , Khajouei, Farzaneh , Sikkink, Kristin , Li, Yong , Young, Ken H , Xu‐Monette, Zijun Y. , Tzankov, Alexandar , Cao, Xin , Zu, Youli , Montes‐Moreno, Santiago , Krieken, J. Han van , Ponzoni, Maurilio , Parsons, Benjamin M. , Li, Yong , Hastie, Alex R. , Young, Ken H.

Mayo Clinic

Blood Advances | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026019675 | PMID 42308239 Get It

Diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, arises from various pathogenic mechanisms including gene translocations and fusions. Detection of gene rearrangements using fluorescence in situ hybridization (FISH) is a standard practice for DLBCL diagnosis and guides treatment decisions. High-throughput chromosome conformation capture (Hi-C) DNA sequencing is a next-generation sequencing-based technology to identify genome-wide rearrangements using a single assay. In this study, Hi-C sequencing was performed using FFPE tissues from 159 patients with DLBCL, and identified 746 cancer genes at or proximal to the rearrangement breakpoints with a total of 1903 occurrences. Focusing on clinically important rearrangements, Hi-C detected 102 rearrangements of MYC, BCL2, and/or BCL6 in 92 patients and revealed the fusion partners, including 25 rearrangements missed by FISH. Causes of FISH negative results included FISH-cryptic breakpoints, complex or faint FISH signals, low percentage of FISH positivity, and issues related to tissue fixation. Moreover, in 20 patients (12.6%), Hi-C sequencing detected 22 rearrangements characteristic of other lymphoma types, including CCND1 rearrangements that could lead to reclassification as mantle cell lymphoma. Survival analysis for genome-wide rearrangements using machine learning models identified MYC, PD-L1, CCND1, BCL2, NTRK1/PRCC, RRAS, and FANCE rearrangements with significant prognostic effects in the DLBCL cohort. In conclusion, Hi-C sequencing detects gene rearrangements crucial for diagnosis in an unbiased and molecular manner and showed high sensitivity and specificity in our study. These advantages of Hi-C sequencing offer help to improve the workflow of clinical pathology laboratories, diagnostic precision, and treatment of large B-cell lymphoma.
AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia
Crystal, R G, Weinsaft, Jonathan W. , Kaminsky, S B, Caragiulo, Anthony, Savage, Niamh, Patel, A, Gavrilova, Ralitza H. , Perlman, Susan , Galbraith, Madeline, Kahlon, Udhay, Krishnan, UM, Sanders, Abraham, Vo, Mary, Sarva, Harini, Yoo, Andrea, Sondhi, Dolan , De, Bishnu P., Mezey, Jason G. , Khan, Aashir, Selvan, Nithya, Bhalla, N P, Adler, Eric, Zesiewicz, Theresa, Caragiulo, Anthony , Patel, Aarti , Kaner, Robert J. , Yoo, Andrea S. , Aubert, Grégory , Selvan, Nithya, Bhalla, Naman Kumar

Mayo Clinic

JAMA Cardiology | June 17, 2026 | Volume: 11 | Issue: 8 | Pages: 709

10.1001/jamacardio.2026.1699 | PMID 42307907 Get It

Importance Friedreich ataxia (FA), a fatal, autosomal recessive disorder caused by pathogenic variants in the frataxin ( FXN ) gene, is characterized by progressive neurologic and cardiac disease, with cardiac disease being the major cause of death. Preclinical studies have demonstrated that systemic administration of AAVrh.10hFXN, an rh.10 serotype cardiotropic adenoassociated virus (AAV) vector expressing the normal human FXN coding sequence, reverses the cardiomyopathy in FXN-deficient mice. Objective To assess the safety and preliminary efficacy of administration of AAVrh.10hFXN to adults with FA cardiomyopathy. Design, Setting, and Participants This nonrandomized clinical trial evaluates the pooled data of 2 independent, open-label, dose-escalation trials that used the same gene therapy vector and similar clinical protocols among patients with FA cardiomyopathy at academic medical centers. Data were collected from February 22, 2022, to October 4, 2025, for trial 1 and from February 14, 2023, to September 10, 2025, for trial 2 and analyzed together from November 5, 2025, to March 12, 2026. Intervention AAVrh.10hFXN, administered intravenously in 3 dose cohorts (1.8 × 10 11 , 5.6 × 10 11 , and 1.2 × 10 12 vector genomes per kilogram of body weight). Main Outcomes and Measures In addition to safety as the primary outcome, multiple parameters of exploratory end points were assessed, including cardiac biopsy levels of FXN protein, cardiac magnetic resonance imaging–derived left ventricular mass index (LVMI), and serum high-sensitivity (hs) troponin I. Results Seventeen patients with FA cardiomyopathy (mean [SD] age, 25 [6] years; 11 [65%] female) were followed up for a mean (SD) of 20 (8) months. There were 4 serious adverse events, 3 possibly related to prednisone immunosuppression and 1 possibly vector-related myocarditis 12 months after therapy, all of which resolved. Other adverse events were transient, nonserious, or not treatment related. In all 8 patients with cardiac biopsy 3 months after therapy, there were higher levels of cardiac FXN (dose cohort 1, 20%; cohort 2, 81%; cohort 3, 123%). After therapy, LVMI was lower by at least 10% in 9 patients and stabilized in 8 patients. Excluding the patient with myocarditis, posttherapy values of serum hs troponin I were lower by at least 10% in 15 patients and higher by at least 10% in 2 patients. Conclusions and Relevance Findings of this nonrandomized clinical trial suggest that intravenous administration of AAVrh.10hFXN was well tolerated and may be a potential treatment for FA cardiomyopathy, as evidenced by preliminary improvement in exploratory efficacy end points. Trial Registration ClinicalTrials.gov Identifiers: NCT05302271 and NCT05445323
Brain regional susceptibility to tauopathy in individuals at risk for chronic traumatic encephalopathy
Wiegand, Tim L. T., Rubinski, Anna, Jung, Leonard B., Franzmeier, Nicolai, Arciniega, Hector , Ravanfar, Parsa , Alosco, Michael L., Tripodis, Yorghos, Su, Yi, Protas, Hillary, Lin, Alexander P., Pasternak, Ofer, Chen, Kewei, Bouix, Sylvain, Adler, Charles H., Balcer, Laura J. , Bernick, Charles, Cummings, Jeffrey L., Stern, Robert A., Reiman, Eric M., Shenton, Martha E., Ewers, Michael, Wiegand, Tim L. T. , Koerte, Inga K , Rubinski, Anna , Jung, Leonard , Franzmeier, Nicolai , Dewenter, Anna , Alosco, Michael L. , Tripodis, Yorghos , Su, Yi, Protas, Hillary , Pasternak, Ofer , Coleman, Michael , Bouix, Sylvain , Adler, Charles H. , Bernick, Charles , Reiman, Eric M. , Shenton, Martha E. , Ewers, Michael

Mayo Clinic

Alzheimer's & Dementia | June 17, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71503 | PMID 42304137 Get It

Abstract INTRODUCTION Chronic traumatic encephalopathy (CTE) is a tauopathy linked to repetitive head impacts. Factors influencing brain regional susceptibility to tau deposition and spreading remain unclear. METHODS We used three datasets: [18F]flortaucipir positron emission tomography (PET) in 157 former professional American football players and 53 controls (DIAGNOSE CTE); cortical myelin water fractions (MWF) in 50 healthy individuals (Myelin Water Atlas); and white matter (WM) tract MWF and functional connectivity (FC) in 100 healthy individuals (Human Connectome Project). We tested associations between tau‐PET uptake and covariance in football players and typical cortical gray matter (GM) MWF, WM tract MWF, and FC. RESULTS Cortical regions with lower typical GM MWF showed higher tau‐PET uptake ( β = −0.399, p = 0.001). WM tracts with lower typical MWF were associated with higher tau‐PET covariance ( β = −0.238, p < 0.001). Higher typical FC was associated with higher tau‐PET covariance ( β = 0.447, p < 0.001). DISCUSSION In former football players at risk for CTE, regional susceptibility to tau deposition may be driven by low myelin and high FC.